However, certain GPCR-based medicines, such as blockers and dopamine, have been shown to have considerable impacts on cardiac and psychological functioning; therefore, negative consequences must be addressed before employing these medications in cancer therapy [257,258]. Here, LPAR3 is linked to cancer.